Drug intelligence / Profile preview

parimparib

Development stage: Unknown
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

Parimparib is an investigational small molecule drug described in at least one clinical trial as a poly(ADP-ribose) polymerase (PARP) inhibitor. It is being studied for its potential antineoplastic activity, particularly in patients with non-small cell lung cancer (NSCLC) that is resistant to EGFR tyrosine kinase inhibitors. The mechanism of action involves inhibition of PARP enzymes, which play a key role in DNA repair; by inhibiting these enzymes, parimparib may enhance the cytotoxicity of DNA-damaging agents and promote cancer cell death.

Targets

PARP2 (Poly (adp-ribose) polymerase 2)

Beyond the preview

Go deeper on parimparib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on parimparib.

Explore the full profile